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Abstract
Background: Several factors contribute to the deterioration in synaptic plasticity which accompanies age and one
of these is neuroinflammation. This is characterized by increased microglial activation associated with increased
production of proinflammatory cytokines like interleukin-1β (IL-1β). In aged rats these neuroinflammatory changes
are associated with a decreased ability of animals to sustain long-term potentiation (LTP) in the dentate gyrus.
Importantly, treatment of aged rats with agents which possess anti-inflammatory properties to decrease microglial
activation, improves LTP. It is known that endocannabinoids, such as anandamide (AEA), have anti-inflammatory
properties and therefore have the potential to decrease the age-related microglial activation. However,
endocannabinoids are extremely labile and are hydrolyzed quickly after production. Here we investigated the
possibility that inhibiting the degradation of endocannabinoids with the fatty acid amide hydrolase (FAAH)
inhibitor, URB597, could ameliorate age-related increases in microglial activation and the associated decrease in LTP.
Methods: Young and aged rats received subcutaneous injections of the FAAH inhibitor URB597 every second day
and controls which received subcutaneous injections of 30% DMSO-saline every second day for 28 days. Long-term
potentiation was recorded on day 28 and the animals were sacrificed. Brain tissue was analyzed for markers of
microglial activation by PCR and for levels of endocannabinoids by liquid chromatography coupled to tandem
mass spectrometry.
Results: The data indicate that expression of markers of microglial activation, MHCII, and CD68 mRNA, were
increased in the hippocampus of aged, compared with young, rats and that these changes were associated with
increased expression of the proinflammatory cytokines interleukin (IL)-1β and tumor necrosis factor-α (TNFα) which
were attenuated by treatment with URB597. Coupled with these changes, we observed an age-related decrease in
LTP in the dentate gyrus which was partially restored in URB597-treated aged rats. The data suggest that
enhancement of levels of endocannabinoids in the brain by URB597 has beneficial effects on synaptic function,
perhaps by modulating microglial activation.
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Introduction
Endocannabinoids are lipid-derived molecules which,
in the brain, are synthesized by both astrocytes and
microglia [1,2]. The two most studied endocannabi-
noids are anandamide (AEA) which is hydrolyzed by
fatty acid amide hydrolase (FAAH) and 2-arachido-
noylglycerol (2-AG), which is hydrolyzed by FAAH
and monoacylglycerol lipase (MAGL) [3,4]. FAAH
also catalyzes the hydrolysis of the N-acylethanola-
mines, N-palmitoyl ethanolamide (PEA), and N-oleoyl
ethanolamide (OEA) [5], which, though not them-
selves endocannabinoids, can compete with AEA as
substrates for FAAH and therefore increase AEA
levels via the so-called ‘entourage effect’ [6]. To date,
two cannabinoid receptors have been cloned; in the
brain, CB1 receptors are expressed predominantly on
neurons, whereas CB2 receptors are expressed mainly
on immune cells, including microglia [7]. Constitutive
expression of CB1 on neurons has been described, but
expression of CB2 in the brain is low under resting
conditions. However CB2 receptor expression on
microglia increases markedly in conditions where
neuroinflammatory changes occur for example in
multiple sclerosis and Alzheimer’s disease [8,9] and in
the lesioned striatum in an animal model of Hunting-
ton’s disease [10]. Interestingly, increased CB2 receptor
expression has been demonstrated on the microglia that
surround amyloid-β (Aβ)-containing plaques in Alzheimer’s
disease [8,11].
The neuroprotective effects of endocannabinoids
have been carefully described by several groups, for
example following neurotoxic stimuli [12,13] and Aβ
treatment [14]. The ability of cannabinoids to modu-
late the adaptive and innate branches of the immune
system has been recognized for several years [15]
and, in the context of the CNS, a great deal of em-
phasis has been placed on evaluating the effects of
cannabinoids in multiple sclerosis and particularly
the animal model, experimental autoimmune enceph-
alomyelitis (EAE; [16]). The ability of the cannabin-
oid delta(9)-tetrahydrocannibinol (THC) to decrease
inflammation in the spinal cord of animals in which
EAE was induced, was reported over two decades
ago [17] and several studies have supported this
finding with recent evidence indicating that symp-
toms and inflammatory changes, including microglial
activation, were more profound in CB2 receptor
knockout mice [18]. The cannabinoid agonist, (R)-
(+)-[2, 3-dihydro-5-methyl-3-(4-morpholinylmethyl)-
pyrrolo[1,2,3-de-1,4benzoxazin-6-yl]-1-naphthalenyl-
methanone mesylate (WIN-55,212-2) has been shown to
attenuate the microglial activation observed in brain of
animals which received an intracerebraventricular injec-
tion of Aβ25-35 and it also attenuated the Aβ-associated
decrease in neuronal proteins and deficits in spatial
learning [11]. Consistently, a number of in vitro stud-
ies have demonstrated that endocannabinboids and/or
synthetic cannabinoids attenuate microglial activation
induced by interferon-γ (IFNγ) [19], Aβ [11], or lipo-
polysaccharide (LPS) [20,21].
A good deal of evidence indicates that microglial acti-
vation increases with age and this is closely linked with
the age-related deficit in synaptic plasticity, particularly
long-term potentiation (LTP) [22,23] and it has been
shown that LTP is sustained in aged rats by interven-
tions which decrease microglial activation [22,24,25]. An
age-related deficit in spatial learning, which is another
form of synaptic plasticity, has also been reported and
interestingly, when aged rats were treated with WIN-
55,212-2, performance in a spatial learning task
improved and this was correlated with a decrease in the
number of activated microglia in CA3 but not in the
dentate gyrus [26].
We hypothesized that administration of the FAAH in-
hibitor, URB597, which, by decreasing AEA hydrolysis,
would increase endocannabinoid tone and therefore de-
crease the age-related microglial activation and conse-
quently enable aged rats to sustain LTP. The data indicate
that administration of URB597, increased brain tissue con-
centrations of AEA, and other N-acylethanolamines, atte-
nuated the increased expression of several markers of
microglial activation in aged animals and improved the abil-
ity of aged rats to sustain LTP.
Materials and methods
Animals
Young (3 months; 250–350 g) and aged (26–30 months;
550–600 g) male Wistar rats (B&K Universal, Hull, UK)
were housed in a controlled environment (temperature
20-22°C; 12:12 h light/dark cycle) in the BioResources
Unit, Trinity College, Dublin. Animals had free access to
food and water and were maintained under veterinary
supervision for the duration of the experiment. Young and
aged rats were randomly divided into those which
received subcutaneous injections of the FAAH inhibitor
URB597 (1 mg/kg; dissolved in 30% DMSO, saline) every
second day and controls which received subcutaneous
injections of 30% DMSO-saline every second day for 28
days. All experiments were carried out under license from
the Department of Health and Children (Ireland) and with
ethical approval from the Trinity College Ethical
Committee.
Analysis of LTP in vivo
Rats were anaesthetized by intraperitoneal injection of
urethane (1.5 g/kg) and the absence of a pedal reflex was
considered to be an indicator of deep anesthesia; in
some animals a top-up dose of urethane (to a maximum
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of 2.0 g/kg) was required to establish deep anesthesia.
The ability of rats to sustain LTP in perforant path-gran-
ule cell synapses in response to tetanic stimulation of
the perforant path was assessed as previously described
[27]. Briefly, a bipolar stimulating electrode was stereo-
taxically positioned in the perforant path (4.4 mm lateral
to Lambda) and a unipolar recording electrode was
placed in the dorsal cell body region of the dentate gyrus
(2.5 mm lateral and 3.9 mm posterior to Bregma). Fol-
lowing a period of stabilization, test shocks were deliv-
ered at 30-s intervals and responses were recorded for
10 min to establish stable baseline recordings. LTP was
induced by delivering three trains of high-frequency
stimuli (250 Hz for 200 ms; 30 second inter-train inter-
val). Recording at test shock frequency resumed for the
remainder of the experiment. The slope of the excitatory
post-synaptic potential (EPSP) was used as a measure of
excitatory synaptic transmission in the dentate gyrus.
At the end of the experiment, rats were killed by cer-
vical dislocation and brain tissue was dissected free. Tissue
was snap-frozen and used to prepare mRNA for PCR ana-
lysis or for the quantification of endocannbinoids.
Real-time PCR analysis of cytokines and cell surface
markers
Total RNA was extracted from snap-frozen hippocampal
and cortical tissue using a NucleoSpinW RNAII isolation
kit (Macherey-Nagel Inc., Germany) according to the
manufacturer’s instructions. RNA integrity and total RNA
concentration were assessed, and cDNA synthesis was
performed as described previously [28]. Real-time PCR
was performed using Taqman Gene Expression Assays
(Applied Biosystems, Germany) which contain forward
and reverse primers, and a FAM-labeled MGB Taqman
probe for each gene of interest. The assay IDs for the
genes examined in this study were as follows: MHCII
(Rn01768597_m1), CD40 (Mm00441895_m1), CD11b
(Mm001271265_m1), CD68 (Rn01495631_g1), IL-1β
(Rn00580432_m1), TNFα (Mm00443258_m1), and IL-6
(Mm00446191_m1). All real-time PCR was conducted
using an ABI Prism 7300 instrument (Applied Biosys-
tems, Germany). A 20 μl volume was added to each
well containing 8 μl of cDNA (1:4 dilution), 1 μl of
target gene primer, and 10 μl of TaqmanW Universal
PCR Master Mix). Samples were assayed in duplicate
in one run (40 cycles), which consisted of three
stages, 95°C for 10 min, 95°C for 15 s for each cycle
(denaturation), and finally the transcription step at
60°C for 1 min. β-actin was used as endogenous con-
trol to normalize gene expression data, and β-actin
expression was conducted using a gene expression
assay containing forward and reverse primers (primer
limited) and a VIC-labeled MGB Taqman probe from
Applied Biosystems (Germany; Assay ID: 4352341E).
Gene expression was calculated relative to the endogenous
control samples and to the control sample giving an RQ
value (2− DDCt, where CT is the threshold cycle).
Quantitation of endocannabinoids and N-
acylethanolamines in cerebellar tissue using liquid
chromatography coupled to tandem mass spectrometry
(LC-MS/MS)
Brains from the young and aged, vehicle or URB597 trea-
ted rats were removed rapidly and the cerebellum was
gross-dissected (average weight of tissue samples = 158.26
mg), snap-frozen on dry ice and stored at -800 C prior to
extraction and determination of the concentrations of
the endocannabinoids anandamide (AEA) and 2-arachi-
donoyl glycerol (2-AG) and the related N-acylethanola-
mines N-palmitoyl ethanolamide (PEA) and N-oleoyl
ethanolamide (OEA) by liquid chromatography coupled
to tandem mass spectrometry (LC-MS/MS) as described
previously [29,30]. Each tissue sample was first homoge-
nized in 400 μL 100% acetonitrile containing known fixed
amounts of deuterated internal standards (0.014 nmol
AEA-d8, 0.48 nmol 2-AG-d8, 0.016 nmol PEA-d4, 0.015
nmol OEA-d2). Homogenates were centrifuged at 14,000
g for 15 min at 4°C and the supernatant was collected
and evaporated to dryness in a centrifugal evaporator.
Lyophilized samples were re-suspended in 40 μL 65%
acetonitrile and 2 μL were injected onto a ZorbaxW C18
column (150 × 0.5 mm internal diameter) from a cooled
autosampler maintained at 4°C (Agilent Technologies
Ltd, Cork, Ireland). Mobile phases consisted of A (HPLC
grade water with 0.1% formic acid) and B (acetonitrile
with 0.1% formic acid), with a flow rate of 12 μL/min.
Reversed-phase gradient elution began initially at 65% B
and over 10 min was ramped linearly up to 100% B. At
10 min, the gradient was held at 100% B up to 20 min. At
20.1 min, the gradient returned to initial conditions for a
further 10 min to re-equilibrate the column. The total
run time was 30 min. Under these conditions, AEA, 2-
AG, PEA, and OEA eluted at the following retention
times: 11.36 min, 12.8 min, 14.48 min, and 15.21 min, re-
spectively. Analyte detection was carried out in electro-
spray-positive ionization mode on an Agilent 1100 HPLC
system coupled to a triple quadrupole 6460 mass spec-
trometer (Agilent Technologies Ltd., Cork, Ireland). In-
strument conditions and source parameters including
fragmentor voltage and collision energy were optimized
for each analyte of interest prior to assay of samples.
Quantitation of target endocannabinoids was achieved by
positive ion electrospray ionization and multiple reactions
monitoring (MRM) mode, allowing simultaneous detec-
tion of the protonated precursor and product molecular
ions [M+H+] of the analytes of interest and the deuter-
ated forms of the internal standards. Quantitation of each
analyte was performed by determining the peak area
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response of each target analyte against its corresponding
deuterated internal standard. This ratiometric analysis was
performed using Masshunter Quantitative Analysis Soft-
ware (Agilent Technologies Ltd., Cork, Ireland). The
amount of analyte in unknown samples was calculated
from the analyte/internal standard peak area response
ratio using an 11-point calibration curve constructed
from a range of concentrations of the non-deuterated
form of each analyte and a fixed amount of deuterated in-
ternal standard. The values obtained from the Masshun-
ter Quantitative Analysis Software are initially expressed
in ng per mg of tissue by dividing by the weight of the
punched tissue. To express values as nmol or pmol per
mg the corresponding values are then divided by the
molar mass of each analyte expressed as ng/nmole or pg/
pmole. Linearity (regression analysis determined R2
values of 0.99 or greater for each analyte) was determined
over a range of 75 ng to 71.5 fg except for 2-AG which
was 750 ng to 715 fg. The limit of quantification was 1.32
pmol/g, 12.1 pmol/g, 1.5 pmol/g, and 1.41 pmol/g for
AEA, 2-AG, PEA, and OEA, respectively.
Statistical analysis
Prism GraphPadW was used for statistical analysis. Data
were analyzed using analysis of variance (ANOVA) with
Newman Keuls post-hoc test to determine which condi-
tions were significantly different from each other. Data
are expressed as means with standard errors.
Results
MHCII, CD68, and CD11b mRNA were increased in hip-
pocampal tissue prepared from aged, compared with young,
rats and the evidence indicates that these measures of
microglial activation were decreased in tissue prepared
from aged rats which were treated with URB597. A signifi-
cant age x treatment interaction was observed for MHCII
mRNA (F(1,22) = 8.84, **P< 0.01; Figure 1a), CD11b mRNA
(F(1,22) = 6.22, *P< 0.05; Figure 1b) and CD68 mRNA
(F(1,22) = 4.80, *P< 0.05; Figure 1c), whereas a significant
age effect was observed in the case of CD40 mRNA
(F(1,21) = 14.09,
++P< 0.01; Figure 1d).
Activated microglia are a major source of inflammatory
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Figure 1 Age-related microglial activation in hippocampus is attenuated by URB597. URB597 attenuated the age-related increase in MHCII
mRNA, CD68 mRNA, and CD11b mRNA in hippocampal tissue and the analysis revealed a significant age x treatment interaction for MHCII mRNA
(F(1,22) = 8.84, **P< 0.01; 2-way ANOVA; a), CD11b mRNA (F(1,22) = 6.22, *P< 0.05; b), and CD68 mRNA (F(1,22) = 4.80, *P< 0.05; c). A significant age
effect was observed in the case of CD40 mRNA (F(1,21) = 14.09,
++P< 0.01; d).
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increase in microglial activation was associated with evi-
dence of increased production of inflammatory cytokines.
There was an increase in IL-1β, TNFα, and IL-6 mRNA in
hippocampal tissue prepared from aged, compared with
young, rats; a significant age x treatment effect was
observed in both IL-1β and TNFα (F(1,22) = 5.096, **P
< 0.01; 2-way ANOVA; Figure 2a and F(1,21) = 16.16, **P
< 0.01; Figure 2b, respectively) whereas a significant age ef-
fect was observed in the case of IL-6 (F(1,21) = 29.98,
++P
< 0.01; 2-way ANOVA; Figure 2c).
Similar age-related increases in expression of MHCII,
CD68, CD40, and CD11b mRNA were observed in cor-
tical tissue. Analysis of the data indicated a significant
age x treatment interaction in the case of MHCII mRNA
(F(1,23) = 9.11, **P< 0.01; 2-way ANOVA; Figure 3a)
whereas significant age effects were observed in the case
of CD11b (F(1,20) = 44.86,
+++P< 0.001; Figure 3b), CD68
(F(1,22) = 14.81,
+++P< 0.001; Figure 3c), and CD40
mRNA (F(1,20) = 5.62,
+P< 0.05; Figure 3d). In parallel
with the changes in hippocampus, expression of IL-
1β, TNFα, and IL-6 mRNA were increased in cortical
tissue prepared from aged, compared with young,
rats. A significant age effect was observed in the case
of IL-1β (F(1,22) = 5.97,
+P< 0.05; 2-way ANOVA;
Figure 3e), TNFα (F(1,23) = 9.98,
++P< 0.01; Figure 3f) and
IL-6 (F(1,26) = 20.91,
++P< 0.01; Figure 3g). URB597 had
no significant effects on the age related increases in the
expression of IL-1β, TNFα, or IL-6 mRNA in the cortex
(Figure 3e, f, and g).
A key question was to assess whether URB597, by modu-
lating microglial activation, might improve the ability of
aged rats to sustain LTP. Delivery of a high frequency train
of stimuli to the perforant path induced an immediate and
sustained increase in EPSP slope in young control-treated
rats (Figure 4a) whereas the initial increase in EPSP slope
in aged control-treated rats was temporary and the mean
value returned to baseline after about 10 min. However
aged rats which received URB597 sustained LTP to the
same extent as young control-treated rats and URB597
enhanced the ability of young rats to sustain LTP. Analysis
of the mean data in the 5 min immediately following tetanic
stimulation revealed a significant age effect (F(1,8) = 16.73,
++P< 0.01; 2-way ANOVA; Figure 4b) while analysis of
the data in the last 5 min of recording indicated that there
was a significant age x treatment interaction (F(1,8) = 444.1,
***P< 0.001; 2-way ANOVA; Figure 4c) indicating that
treatment of aged animals with URB597 attenuated the
impairment in LTP.
Tissue concentrations of endocannabinoids and
related N-acylethanolamines in the cerebellum were
assessed by liquid chromatography coupled to tandem
mass spectrometry and analysis of the data obtained for
AEA revealed a significant treatment effect (F(1,23) = 6.29,
+P
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Figure 2 URB597 treatment attenuates the age-related increase in
inflammatory cytokines in hippocampus. IL-1β, TNFα, and IL-6 mRNA
were increased in hippocampal tissue prepared from aged, compared
with young, rats; a significant age x treatment effect was observed for IL-
1β and TNFα (F(1,22) = 5.096, **P< 0.01; and F(1,21) = 16.16, **P< 0.01; 2-
way ANOVA; a and b, respectively) and a significant age effect was
observed in the case of IL-6 (F(1,21) = 29.98,
++P< 0.001; c).
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Figure 3 (See legend on next page.)
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analysis of the data obtained for OEA and PEA indicated
that there were significant treatment effects in both cases
(F(1,23) = 35.30,
+++P< 0.001; ###P< 0.001; 2-way ANOVA;
Figure 5b and c). No significant treatment effect was
observed in the case of 2-AG (Figure 5d).
Discussion
The aim of this study was to assess whether the age-related
increase in microglial activation and the associated decrease
in LTP were attenuated by chronic administration of the
FAAH inhibitor, URB597. The data show that URB597
increased AEA, OEA, and PEA and that this was accom-
panied by a URB597-associated attenuation of the age-
related neuroinflammatory changes and also the age-related
impairment in LTP.
Increased expression of MHCII, CD11b, CD68, and
CD40, which are commonly-used markers of microglial
activation, were observed in hippocampus and also the
















































Figure 4 URB597 treatment attenuates the age-related decrease in LTP in dentate gyrus. (a) Delivery of a high frequency train of stimuli to the
perforant path at time 0 induced an immediate and sustained increase in EPSP slope in control young rats and this effect was markedly decreased in
control aged rats. Aged rats treated with URB597 sustained LTP in a manner similar to young animals. (b) The mean changes in EPSP slope in the 5 min
immediately following tetanic stimulation revealed a significant age effect (F(1,8) = 16.73, ++P< 0.01; 2-way ANOVA; b) and analysis of the data in the last 5
min of recording indicated that there was a significant age x treatment interaction (F(1,8) = 444.1, ***P< 0.001; 2-way ANOVA; c).
(See figure on previous page.)
Figure 3 URB597 treatment attenuates age-related changes in cortex. Increased expression of MHCII, CD11b, CD68, and CD40 mRNA were
observed in cortex of aged, compared with young, rats. A significant age x treatment effect in the case of MHCII mRNA (F(1,23) = 9.11, **P< 0.01;
2-way ANOVA; a) and significant age effects were observed in the case of CD11b (F(1,20) = 44.86,
+++P< 0.001; b), CD68 (F(1,22) = 14.81,
++
+P< 0.001; c) and CD40 mRNA (F(1,20) = 5.62,
+P< 0.05; d). Significant age effects were also observed in IL-1β (F(1,22) = 5.97, +P< 0.05; 2-way
ANOVA; e), TNFα (F(1,23) = 9.98, ++P< 0.01; f) and IL-6 (F(1,26) = 20.91, ++P< 0.01; g).
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cortex of aged, compared with young rats. This concurs
with previously-reported findings which demonstrated
that these, and other markers of microglial activation,
were increased with age [24,31,32]. One of the most sig-
nificant findings of this study is that these changes were
attenuated in hippocampal and cortical tissue prepared
from aged rats which received URB597. Cannabinboids
are known to modulate certain aspects of microglial
function in vitro; for instance the phytocannabinoid
THC and the non-hydrolyzable analogue of anandamide,
methanandamide, decreased LPS-induced cytokine pro-
duction from rat cortical glial cells [21,33], while AEA
and 2-AG, as well as a number of synthetic cannabi-
noids, inhibited the LPS-induced release of TNFα [20]
and the generation of nitrites [34] from cultured glial
cells. At least in some studies [20,33], the actions of the
cannabinoids were not CB receptor mediated. There are
other reports of a similar modulatory effect of synthetic
cannabinoids on microglial activation in vitro including
their ability to attenuate the ATP-induced increase in
intracellular calcium concentration [34] and the neurotox-
icity induced by Aβ-treated microglia [11]. Similarly the
LPS-induced release of TNFα and IL-1β from cultured
astrocytes was attenuated by both anandamide and the
anandamide uptake inhibitor, UCM707 [35]. In addition to
these effects in vitro, it has been shown that the increase in
microglial activation induced by the central administration
of LPS to rats for 21 days [26] or by daily intracerebroven-
tricular injection of Aβ25-35 for 7 days [11] was attenuated
by subcutaneously- or centrally-administered WIN55,212-
2, respectively.
While a number of cells produce inflammatory cyto-
kines, activated microglia are considered to be a primary
source of cytokines such as IL-1β, IL-6, and TNFα in the
brain. The present data indicate that the age-related in-
crease in markers of microglial activation are accompanied
by an increase in these cytokines confirming earlier reports
of a similar parallel [36]. The increase in cytokine produc-
tion was markedly reduced in hippocampal tissue prepared
from aged rats which received URB597 providing evidence
of an anti-inflammatory effect of the FAAH inhibitor.
URB597 treatment has been shown to decrease LPS-
induced PGE2 production in cultured microglia though it
did not attenuate the increases in COX2 and iNOS [37].
Intra-peritoneal injections of URB597 have also been




















































Figure 5 URB597 treatment increased concentrations of the endocannabinoid AEA and the N-acylethanolamines OEA and PEA. Analysis
of the analyte concentrations revealed a significant treatment effect for AEA (F(1,23) = 6.29, +P< 0.05; #P< 0.05; 2-way ANOVA; a), OEA (F
(1,23) = 35.30,
+++P< 0.001; ###P< 0.001; b) and PEA (F(1,23) = 29.21,
+++P< 0.001; ###P< 0.001; c) and a significant age x treatment interaction was
observed in the case of 2-AG (F(1,23) = 4.86, **P< 0.01; d).
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hypothalamus in Sprague-Dawley rats [38]. The synthetic
cannabinoid, dexanabinol, which facilitated recovery and
decreased cell death, reduced hippocampal expression of
TNFα and IL-1β in the hippocampus after traumatic brain
injury [39]. Perhaps in contrast with this is the report that
the CB2 agonist JWH-133, which decreased infarct volume
following middle cerebral artery occlusion, did not attenu-
ate the increase in TNF or IL-1β in ischaemic brain tissue
[40].
In the past few years, it has become increasingly clear
that neuroinflammation negatively impacts on neuronal
plasticity [36] and specifically that LTP is decreased when
microglial activation and/or inflammatory cytokine pro-
duction is increased in hippocampus [24,36,41]. The
present findings provide support for this inverse correl-
ation, specifically demonstrating that LTP was decreased
in dentate gyrus of aged rats. Significantly, the age-related
deficit in LTP was attenuated by treatment with URB597
in parallel with its ability to decrease the expression of
several markers of microglial activation and the produc-
tion of inflammatory cytokines in the hippocampus. These
changes concur with the findings of previous studies
which indicated that when the age-related increase in
microglial activation is attenuated, for example with mino-
cycline [25], the anti-inflammatory cytokine IL-4 [23], the
polyunsaturated fatty acids EPA and DPA [32], the choles-
terol-lowering HMGCoA reductase, atorvastatin [41], and
the PPARγ activator, rosiglitazone [42], then the ability of
aged rats to sustain LTP is improved.
A facilitatory effect of cannabinoids on other forms of
synaptic plasticity has also been reported. Thus the syn-
thetic cannabinoid, WIN55,212-2, attenuates the impaired
spatial learning observed in rats which received Aβ25-35
intracerebroventricularly for 7 days [11]. This effect was
coupled with changes in neuronal markers calbindin and
α-tubulin in tissue prepared from the frontal cortex of mice.
Similarly intraperitoneal administration of WIN55,212-2 or
cannabidiol for 3 weeks attenuated the cognitive impair-
ment induced by a single injection of Aβ, although the
CB2 agonists, 1,1-dimethylbutyl-1-deoxy-Δ
9-tetrahydro
cannabinol [JWH-133] and 4-[4-(1,1-dimethylheptyl)-2,6-
dimethoxyphenyl]-6,6-dimethyl-bicyclo[3.1.1]hept-2-ene-2-
methanol [HU-308] did not [34]; in this case the Aβ-
induced increase in IL-6 was attenuated by WIN55,212-2
or cannabidiol prompting the authors to conclude that the
effect of the cannabinoids resulted from modulation of glial
activation. The correlation between glial activation and
spatial learning is not absolute since it has been reported
that while the increase in microglial activation induced by
the central administration of LPS for 21 days was attenu-
ated by WIN55,212-2, treatment with WIN55,212-2 exacer-
bated the deficit in spatial learning [26]. However the same
group reported that when aged rats were treated with
WIN-55,212-2, performance in a spatial learning task
improved and this was correlated with a decrease in the
number of activated microglia in CA3 but not dentate
gyrus [26].
The effect of URB597 in the present study can be attribu-
ted to its ability to increase the concentration of endocan-
nabinoids in the brain. The data indicate that the 28-day
URB597 treatment regime used here increases concentra-
tions of AEA, as well as two other fatty acid ethanolamides,
PEA and OEA in the brain. The anti-inflammatory effects
of AEA have been well documented both in vitro and
in vivo [20,43-46] and both PEA and OEA possess anti-in-
flammatory properties [47,48]. While PEA appears to lack
CB1 receptor binding activity, it interacts with the CB2 re-
ceptor which probably mediates its analgesic and anti-in-
flammatory effects [48-50]. In contrast, OEA may not
interact with either CB1 or CB2 receptors, but rather engage
one of the recently-described G protein-coupled orphan
receptors [51]. It is possible that any of these endocannabi-
noids/N-acylethanolamines, that are increased following
URB597 treatment, may contribute to the anti-inflamma-
tory effects described in the present study.
One of the challenges in neuroscience is to identify
the age-related changes in the brain which present the
most significant risks for development of neurodegen-
erative diseases and to reduce these changes. In addition
to the findings presented here, a good deal of evidence
suggests that neuroinflammation, probably functionally
linked with microglial activation, is one such change.
We demonstrate that increasing endocannabinoid tone
provides a mechanism by which the age-related micro-
glial activation and deficit in synaptic plasticity can be
attenuated.
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